NECTAR IVNCT05369065
Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
At risk: Primary completion moved at least 2 years 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jan 2025 to Jun 2027 Show 5 more changesShow less
- Eligibility criteria expanded, about 71 words
- Enrollment closed, study ongoing
- Study completion pushed from Jan 2029 to Jan 2030
- Secondary endpoints: details revised at 4 of 7 entries
- Site details revised at 3 of 3 sites
Notable Lead sponsor: [Redacted] to Neurotronic, Inc.v2 Show 6 more changesShow less
- Trial status: Withheld to Recruiting
- Primary completion date: Jan 2025
- Study completion date: Jan 2029
- Start date: Jan 27, 2022
- Collaborators expanded, about 2 words
- Study title expanded, about 1 word
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of serious device- and procedure-related complications at 30 days post procedure.
Timeframe: 30 Days
Device success
Timeframe: Procedure Day
Secondary (7)
Glycemic Control - HbA1c
Glycemic Control - fasting glucose
Hypertension Control - ABPM
Hypertension Control - Office Blood Pressure
Procedure success
Show 2 moreShow less
Change of anti-hyperglycemic medications
Change of anti-hypertensive medications
Arms and interventions
Ablation TreatmentExperimental
The participants randomized to this arm will receive Neurotronic ablation treatment.
Sham TreatmentSham comparator
The participants randomized to this arm will have a sham procedure (angiography only)
Single Arm non-Randomized TreatmentExperimental
The participants treated in this arm will receive the Neurotronic ablation treatment
Combination products: Ablation Treatment, Single Arm non-Randomized Ablation Treatment
Diagnostic tests: Arterial Angiography Only
Sites
3 sites in 1 country